Among broad-neutralizers, at one month post-diagnosis, the number of polymorphic sites per individual was significantly higher in individuals with multi-founder infections compared to those with single founders for all Env sites (p = 0.001), surface sites (p = 0.001), CD4bs (p = 0.007) and V1-V2 Ab contact sites (p = 0.022) (Fig 4C). Here, ERVW-1 is linked to infection.